Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 186HER2-positive Breast Cancer 18Neoplasms 13Neoplasm Metastasis 11Prostatic Neoplasms 7Ovarian Neoplasms 7Stomach Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Inflammatory Breast Neoplasms 5Colonic Neoplasms 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Multiple Myeloma 4Hematologic Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 4Urinary Bladder Neoplasms 3Solid Tumor 3Rectal Neoplasms 3Pathologic Complete Response 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3HER2-positive Early Breast Cancer 3Esophageal Neoplasms 3Breast Neoplasms, Male 3Biliary Tract Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Salivary Gland Neoplasms 2Locally Advanced Breast Cancer 2

Interventions

Fulvestrant 3palbociclib 2Letrozole 2Anastrozole 2venetoclax 1pyrotinib 1pertuzumab 1penpulimab 1dalpiciclib 1anlotinib 1Tretinoin 1Trastuzumab 1Ropivacaine 1Radiosurgery 1Propofol 1Patient Reported Outcome Measures 1Paclitaxel 1Ondansetron 1Morphine 1Induction Chemotherapy 1Etoricoxib 1Docetaxel 1Diagnostic Imaging 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasm Female × pertuzumab × Clear all
NCT05969184 2023-08-01

Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

Peking University Cancer Hospital & Institute

Phase 2 Unknown
94 enrolled
Breast

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡